New drug combo aims to shrink Hard-to-Treat tumors
NCT ID NCT07229638
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests a new drug called SHR-9839 combined with other cancer treatments in people with advanced solid tumors. The goal is to see if the combination is safe, tolerable, and effective at shrinking tumors. About 70 adults aged 18 to 70 with measurable tumors and good performance status are being enrolled.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMOR are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Fudan University Affiliated Cancer Hospital
RECRUITINGShanghai, Shanghai Municipality, 200032, China
-
The First Affiliated Hospital of Nanjing Medical University, Jiangsu Provincial People's Hospital
RECRUITINGNanjing, Jiangsu, 210029, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a new drug shield nerves from Chemotherapy's side effects?
- Can your own immune cells beat advanced cancer?
- Can a Tumor's DNA guide better cancer care for kids?
- Tumor DNA mapping may unlock personalized cancer therapies
- Can a new drug combo shrink Hard-to-Treat tumors?
- Can a new PET tracer reveal a key cancer target?